Surgical resection of a retroperitoneal liposarcoma producing insulin-like growth factor II: a case report.
Hypoglycemia
Insulin-like growth factor
Liposarcoma
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
08 Feb 2023
08 Feb 2023
Historique:
received:
22
12
2022
accepted:
11
01
2023
entrez:
8
2
2023
pubmed:
9
2
2023
medline:
9
2
2023
Statut:
epublish
Résumé
Tumor-produced high molecular weight insulin-like growth factor-II (big insulin-like growth factor-II) is considered to cause non-islet cell tumor hypoglycemia. This paper presents a case of surgically resected retroperitoneal liposarcoma that produced big insulin-like growth factor-II. Here, we report the case of a 62-year-old woman who presented with an abdominal mass and hypoglycemia. Non-islet cell tumor hypoglycemia due to retroperitoneal liposarcoma was suspected. After complete resection of the tumor, the patient's hypoglycemia improved and big insulin-like growth factor-II disappeared in the molecular weight analysis of serum insulin-like growth factor-II by western blotting. The patient had no tumor recurrence or reappearance of hypoglycemia 16 months after the operation without any adjuvant therapy. Although insulin-like growth factor-II-producing tumors are generally large and difficult to operate on, surgical resection is currently the most effective and only treatment; thus, it is essential to attempt resection aggressively.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor-produced high molecular weight insulin-like growth factor-II (big insulin-like growth factor-II) is considered to cause non-islet cell tumor hypoglycemia. This paper presents a case of surgically resected retroperitoneal liposarcoma that produced big insulin-like growth factor-II.
CASE PRESENTATION
METHODS
Here, we report the case of a 62-year-old woman who presented with an abdominal mass and hypoglycemia. Non-islet cell tumor hypoglycemia due to retroperitoneal liposarcoma was suspected. After complete resection of the tumor, the patient's hypoglycemia improved and big insulin-like growth factor-II disappeared in the molecular weight analysis of serum insulin-like growth factor-II by western blotting. The patient had no tumor recurrence or reappearance of hypoglycemia 16 months after the operation without any adjuvant therapy.
CONCLUSIONS
CONCLUSIONS
Although insulin-like growth factor-II-producing tumors are generally large and difficult to operate on, surgical resection is currently the most effective and only treatment; thus, it is essential to attempt resection aggressively.
Identifiants
pubmed: 36752872
doi: 10.1186/s40792-023-01589-9
pii: 10.1186/s40792-023-01589-9
pmc: PMC9908783
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19Informations de copyright
© 2023. The Author(s).
Références
Intern Med. 2006;45(8):525-9
pubmed: 16702745
Endocr J. 2003 Dec;50(6):753-8
pubmed: 14709848
Int J Urol. 2017 Feb;24(2):162-165
pubmed: 28012446
Endocr Rev. 2017 Oct 1;38(5):379-431
pubmed: 28973479
Mod Pathol. 2009 Jul;22(7):914-21
pubmed: 19407853
Cancer Res. 1986 Dec;46(12 Pt 1):6169-73
pubmed: 3779638
Cells. 2020 Oct 12;9(10):
pubmed: 33053840
Growth Horm IGF Res. 2006 Aug;16(4):211-6
pubmed: 16860583
Ann Surg Oncol. 2014 Aug;21(8):2484-9
pubmed: 24756814
J Clin Endocrinol Metab. 2014 Mar;99(3):713-22
pubmed: 24423303
Curr Opin Oncol. 2011 Jul;23(4):373-8
pubmed: 21552124
Mol Genet Metab. 2005 Sep-Oct;86(1-2):84-90
pubmed: 16165387
Pediatr Res. 2018 Jan;83(1-1):183-189
pubmed: 28910276
Lancet Oncol. 2012 Oct;13(10):1045-54
pubmed: 22954508
Int Cancer Conf J. 2022 Apr 20;11(3):210-214
pubmed: 35669897
Intern Med. 2003 Nov;42(11):1151-2
pubmed: 14686761
Diabetes Res Clin Pract. 1990 Nov-Dec;10(3):211-4
pubmed: 2073867
Eur J Endocrinol. 2021 Jan;184(1):41-49
pubmed: 33112286
Surg Oncol Clin N Am. 2016 Oct;25(4):761-73
pubmed: 27591497